Objective This is a retrospective study for risk assessment of acute kidney injury after allogeneic hematopoietic stem cell transplantation (allo HSCT) based on the Acute Kidney Injury Network (AKIN) criteria. Methods Two hundred and eighty-nine consecutive patients who received allo HSCT were studied retrospectively to identify the risk factors for AKI according to the AKIN criteria. The incidence of AKI based on AKIN staging and overall survival (OS) was evaluated using Cox proportional hazard regression models treating each AKIN stage as a time-dependent covariate. Patients We identified a total of 180 patients who developed AKI within 100 days after allo HSCT; AKI was classified as stage 1 in 88 patients (30.5%), stage 2 in 46 patients (15.9%) and stage 3 in 46 patients (15.9%).
Introduction
The concept of acute renal failure (ARF) has now been changed to the new paradigm of acute kidney injury (AKI) (1) . The Acute Dialysis Quality Initiative (ADQI) recently established evidence-based guidelines for the treatment and prevention of ARF (1) . Recognizing the need for a uniform definition for ARF, the ADQI group also proposed new definitions, such as the Risk, Injury, Failure, Loss, and End-stage renal failure classification (RIFLE), and modification was subsequently made by the Acute Kidney Injury Network (AKIN) (2, 3) . The utility of these new definitions has been evaluated mainly in the field of emergency medicine, but few reports are available on AKI associated with allo HSCT (4) . AKI is a common complication early after allo HSCT (5) . Recent reports have shown that AKI results in poor long-term survival and several risk factors were identified for developing AKI following allo HSCT (6) (7) (8) . However, detailed risk assessment based on each AKIN stage has not been fully investigated to date. The present study evaluated the incidence of AKI, as defined by AKIN staging (9) , in patients undergoing allo HSCT. We also performed a retrospective analysis of risk assessment in trans- increased sCre >×2-3 from baseline 3 increased sCre ×3 from baseline or sCre 4mg/dL with an acute increase of at least 0.5mg/dL * AKI was evaluated using only GFR criteria in our study, as data for urine output could not be retrieved.
plant recipients to determine whether each stage of AKI in an allo HSCT setting can be predicted.
Materials and Methods
The subject sample of this retrospective study was comprised of 289 patients who underwent allo HSCT between August 2004 and December 2009. Preparative therapy was basically performed according to the primary disease and type of transplant. Generally, patients with lymphoid malignancy were conditioned using a total body irradiation (TBI)-containing regimen (12 Gy) , including cytarabine at 8 g/m 2 and cyclophosphamide (CY) at 120 mg/kg. Conversely, patients with myeloid malignancy were conditioned using a non-TBI-containing regimen that included intravenous busulfan (BU) at 12.8 mg/kg and CY at 120 mg/kg. Plasma concentrations of BU were not monitored. Total lymphoid irradiation (TLI) to 7 Gy was included in BU/CY regimens in cases with mismatched or unrelated transplantation. Nonmyeloablative allogeneic stem cell transplantation was performed using preparative conditioning comprising CY (120 mg/kg) and fludarabine (125 mg/m 2 ). Cyclosporine (CyA) or tacrolimus (FK) plus short-term methotrexate were used for GVHD prophylaxis. FK was used in cases involving either unrelated or mismatched transplantation (3). Trough level of blood concentration of >400 ng/mL CyA and >20 ng/mL FK were defined as toxic levels. The CyA or FK dose was gradually reduced from day +90 until day +180. Immunosuppression was continued in patients who developed GVHD. Acute and chronic GVHD were diagnosed and graded according to previously established criteria (10) . Most patients received ursodeoxycholic acid as prophylaxis for sinusoidal obstruction syndrome. Tosulfloxacin and fluconazol were orally administered 14 days before allo HSCT. trimethoprim/sulfamethoxazole was administered to prevent Pneumocystis pneumonia. Cytomegalo virus (CMV) infection was monitored weekly according to CMV antigenemia. Positive antigenemia, defined as >1/65,000 cells, was treated using ganciclovir twice daily until negative CMV antigenemia was obtained. Patients switched to foscarnet in case of poor response to ganciclovir or developing pancytopenia. All patients underwent a routine screening blood test including serum creatinine (Cr) at least 3 times per week. In case of any clinical event, additional blood tests were performed. Sepsis was defined as body temperature higher than 38.0 with positive blood culture. Sinusoidal obstruction syndrome (SOS) was considered to be possible when at least two of the following conditions occurred concomitantly after transplantation: jaundice (total bilirubin level >2.0 mg/dL), painful hepatomegaly, and fluid accumulation evidenced by ascites or unexplained body weight gain (>5% above base line weight). Hemorrhagic cystitis (HC) was defined as the presence of sustained macroscopic hematuria more than 10 days after transplantation in the absence of other conditions such as ureteral lithiasis, disseminated intravascular coagulation or multiorgan failure.
Hematopoietic cell Transplantation comorbidity index (HCT-CI) was scored (11) , but the data of diffusing capacity in respiratory function test was not measured in a number of cases. Therefore, diffusing capacity was excluded for scoring in this analysis. AKI was defined and classified into 3 categories according to AKIN criteria (Table 1 ). AKI within the first 100 days after allo HSCT was defined based on serum Cr. Urine output criteria included in the AKIN definition was not used as we were unable to obtain accurate records of urine output from all of the patients (9) 
Statistics
Surviving patients were censored on October, 2010. Categorical variables were compared using the χ 2 test. Associations between several factors and incidence of AKI based on AKIN stage and OS were evaluated using Cox proportional hazard regression model. Age, sex, disease, donor, stem cell source, conditioning regimen were always included in the models. In addition to these variables, the following factors were considered as covariates; cycle of chemotherapies before HSCT, pre-transplant estimated GFR, HCT-CI, TBI dose, toxic level of calcineurin inhibitors (considered as a time-dependent covariate: TDC), acute GVHD, use of amphotericin B (TDC), episode of sepsis (TDC), episode of TMA (TDC), episode of SOS (TDC), and episode of hemorrhagic cystitis (TDC) in analysis of incidence of AKI, and HCT-CI, use of amphotericin B (TDC), acute GVHD (TDC), chronic GVHD (TDC), use of amphotericin B (TDC), episode of sepsis (TDC), disease recurrence (TDC), and episode of AKI (TDC) in the analysis of OS. Backward variable selection was used to construct models. Values of p <0.05 were considered statistically significant. Incidences of non-relapse death in each AKIN category were calculated according to the Kaplan-Meier method, and were compared using log-rank test. All analyses were performed using SAS version 9.2 (SAS institute Inc., Cary, NC, USA). severe aplastic anemia, CB: cord blood stem cell transplantation, BM: bone marrow transplantation, PB: peripheral blood stem cell transplantation, NMA: non myeloablative conditioning, MA: myeloablative conditioning, AMPH-B: amphotericin B, SOS: sinusoidal obstruction syndrome *Backward variable selection was used to construct models, therefore, the variables whose p value had been less than 0.10 were dropped.
Discussion
We retrospectively reviewed 289 allo HSCT recipients, and 180 patients (62.2%) eventually developed AKI at a median time of 41 days (range, 1-100 days) after transplantation (Table 2) . Median age at the time of AKI was 41.5 years (range, 17-66 years) and 111 patients were men (61%). Median follow-up was for 489 days (range, 2-2,256 days). AKI was classified as stage 1 in 88 patients (46.6%), stage 2 in 46 patients (24.3%) and stage 3 in 46 patients (24.3%) according to the AKIN classification. We initially sought to determine which variables were associated with the risk of AKI and we especially focused on the risk assessment based on each AKIN stage. As shown in Table 3 , multivariate analyses of risk factors for each AKIN stage disclosed an episode of SOS as a major cause of any stage of AKI, which are in line with the recent report of risk Figure) , patients with a more severe stage were likely to be followed by more early and late death and causes of death in each stage were summarized in Table 5 . Thus, severity of AKI might contribute to non-relapse death all the way through the transplantation. Although the precise mechanism by which AKI can contribute to long-term poor prognosis is not fully understood, the volume overload, coagulation abnormalities, and cytokine or immune-mediated organ dysfunction may also account for decreased long-term survival of patients who developed AKI (5) . Moreover, chronic kidney disease might ensue as a consequence of previous AKI event (13) , therefore, subsequent hypertension, proteinuria and increased cardiovascular disease could be a possible cause of poor long-term outcome among AKI patients (5) . Specifically, in the setting of allo HSCT, AKI may interfere with dosing of calcineurin inhibitors, and may lead to the development of graft-versus host disease (GVHD) (5).
In conclusion, on the basis of our analysis, sepsis, hemorrhagic cystitis, and acute GVHD were associated with severe AKI, and SOS was associated with any stage of AKI. However, in view of the retrospective nature of the study and the relatively small number of patients, further investigation is necessary to confirm these correlations in analyses of large patient populations.
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